Target- |
MechanismNatural killer cell replacements |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismImmunologic cytotoxicity [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with CellProtect Nordic Pharmaceuticals AB
0 Patents (Medical) associated with CellProtect Nordic Pharmaceuticals AB
100 Deals associated with CellProtect Nordic Pharmaceuticals AB
100 Translational Medicine associated with CellProtect Nordic Pharmaceuticals AB